- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04673617
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 With Immunotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin.
AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells.
This clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab (including the DLBCL specific cohort) or in combination with bendamustine and rituximab; 2) to evaluate the potential clinical activity of AB-101 when given in combination with rituximab or in combination with bendamustine and rituximab (combination cohorts only); and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2 is to determine whether AB-101 in combination with rituximab or in combination with bendamustine and rituximab has anti-cancer activity in patients.
Patients will be assigned to receive either AB-101 alone as monotherapy, in combination with rituximab (including DLBCL specific cohort) or in combination with bendamustine and rituximab. All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and tumor response. Patients receiving AB-101 in combination with rituximab may receive up to 3 additional cycles of treatment. Patients receiving AB-101 in combination with bendamustine and rituximab may receive up to 5 additional cycles of treatment. Patients enrolled into the DLBCL specific cohort receiving AB-101 in combination with rituximab may receive up to 3 cycles of treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: AB-101-01 Study Team
- Phone Number: 858-326-4684
- Email: ab-101-01-study-team@artivabio.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35249
- Recruiting
- University of Alabama
-
Contact:
- Amitkumar Mehta, MD
- Phone Number: 205-966-8400
- Email: amitkumarmehta@uabmc.edu
-
-
Arizona
-
Tucson, Arizona, United States, 85719
- Recruiting
- The University of Arizona Cancer Center - North Clinic
-
Contact:
- Abhijeet Kumar, MD
- Phone Number: 520-694-2873
- Email: akumar1@arizona.edu
-
Principal Investigator:
- Abhijeet Kumar, MD
-
-
California
-
Orange, California, United States, 92868
- Completed
- University of California, Irvine
-
San Diego, California, United States, 92093
- Recruiting
- University of California San Diego Moores Cancer Center
-
Contact:
- Joseph Maroge
- Phone Number: 858-246-0682
- Email: jmaroge@health.ucsd.edu
-
Principal Investigator:
- Ayad Hamdan, M.D.
-
-
Florida
-
Gainesville, Florida, United States, 32608
- Recruiting
- UF Health Shands Cancer Hospital
-
Contact:
- Emma Hall Rosenau, BB(ASCP) SBB, MPH, CCRP
- Phone Number: 352-294-8938
- Email: roseeg@ufl.edu
-
Principal Investigator:
- Erin Dean, MD
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Recruiting
- Blood and Marrow Transplant Group of Georgia at Northside Hospital
-
Principal Investigator:
- Lawrence E Morris, Jr, MD
-
Contact:
- Caitlin Guzowski, MBA, MHA, CCRC
- Phone Number: 404-851-8523
- Email: caitlin.guzowski@northside.com
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Recruiting
- Rush University Medical Center
-
Contact:
- Rush Cancer Center Clinical Trials Office
- Phone Number: 312-226-2371
- Email: cancer_studies@rush.edu
-
Principal Investigator:
- Sunita Nathan, MD
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- University of Iowa Hospitals and Clinics
-
Principal Investigator:
- Umar Farooq, MD
-
Contact:
- Karen Parrott, RN, BSN
- Phone Number: 319-353-6347
- Email: karen-parrott@uiowa.edu
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- Recruiting
- Cancer Center of Kansas
-
Contact:
- Pat Stone, RN
- Phone Number: 316-613-4313
- Email: Pat.stone@cancercenterofkansas.com
-
Contact:
- Lisa Willems
- Phone Number: 316-613-4300
- Email: lisa.willems@cancercenterofkansas.com
-
Principal Investigator:
- Bassam I. Mattar, MD
-
-
Kentucky
-
Louisville, Kentucky, United States, 40241
- Recruiting
- Norton Cancer Institute
-
Contact:
- Norton Cancer Institute Hematology
- Phone Number: 502-899-3366
- Email: Heme-NCIResearch@nortonhealthcare.org
-
Principal Investigator:
- Joseph Maly, M.D.
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Recruiting
- Karmanos Cancer Institute
-
Principal Investigator:
- Dipenkumar Modi, MD
-
Contact:
- Grace Bae
- Phone Number: 313-576-8030
- Email: baeg@karmanos.org
-
-
New York
-
Lake Success, New York, United States, 11042
- Recruiting
- Northwell Health/R. J. Zuckerberg Cancer Center
-
Contact:
- Ruthee-Lu Bayer, MD
- Phone Number: 516-734-8973
- Email: rbayer@northwell.edu
-
Principal Investigator:
- Ruthee-Lu Bayer, MD
-
New York, New York, United States, 11021
- Withdrawn
- Weill Cornell Medicine
-
-
Ohio
-
Columbus, Ohio, United States, 43214
- Recruiting
- OhioHealth Research Institute
-
Contact:
- Basem William, MD
- Phone Number: 614-566-2500
- Email: basem.william@ohiohealth.com
-
Principal Investigator:
- Basem William, MD
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health Sciences Center
-
Contact:
- OHSU Clinical Trials Information Line
- Phone Number: 503-494-1080
- Email: trials@ohsu.edu
-
Principal Investigator:
- Jennifer Saultz, D.O.
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Recruiting
- Fox Chase Cancer Center
-
Contact:
- Rashmi Khanal, M.D.
- Phone Number: 215-728-4300
- Email: Rashmi.Khanal@tuhs.temple.edu
-
Principal Investigator:
- Rashmi Khanal, M.D.
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Jefferson Health
-
Principal Investigator:
- Usama Gergis, MD
-
Contact:
- Natisha Muhmmad, MPH, CCRP
- Phone Number: 215-955-5769
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Recruiting
- Rhode Island Hospital
-
Contact:
- Adam Olszewski, MD
- Email: adam.olszewski@gmail.com
-
Principal Investigator:
- Adam Olszewski, MD
-
-
Texas
-
Dallas, Texas, United States, 75246
- Recruiting
- Texas Oncology - Baylor Charles A. Sammons Cancer Center
-
Principal Investigator:
- Houston Holmes, MD
-
Contact:
- Tarah Satterfield, MPH
- Phone Number: 214-820-6967
- Email: tarah.satterfield@bswhealth.org
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- Huntsman Cancer Institute, University of Utah
-
Contact:
- Boyu Hu, MD
- Phone Number: 801-585-0255
- Email: boyu.hu@hci.utah.edu
-
Principal Investigator:
- Boyu Hu, MD
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Recruiting
- Virginia Commonwealth University
-
Principal Investigator:
- Victor Yazbeck
-
Contact:
- Kristin Lantis
- Email: kllantis@vcu.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Confirmed diagnosis of aggressive NHL of B-cell origin. For enrollment into the DLBCL specific cohort: DLBCL, High-grade B-cell Lymphoma or PMBCL.
- Patient must have progressed or demonstrated intolerance to at least two lines of FDA-approved therapies, one of which must have included anti-CD20 monoclonal antibody therapy. The following are permitted: Prior autologous hematopoietic stem cell transplantation, prior treatment with FDA-approved CAR-T therapy, and/or prior treatment with an investigational agent. Prior treatment(s) with an FDA-approved CAR-T cell therapy or other cell therapies is permitted as long the patients are not considered to be refractory to this previous cell therapy approach (defined as progression within 120 days from the infusion of the cell therapy approach).
- Patient must have disease that allows for response assessment using the Lugano classification criteria.
- Ability to understand and sign the ICF.
Exclusion Criteria:
- Active CNS lymphoma or CNS involvement unless there is a history of at least 3 months of sustained remission of treated disease.
- History of clinically significant structural cardiac disease.
- Cardiac ejection fraction of < 45% on echocardiogram or MUGA scan at screening assessment.
- Inadequate pulmonary function.
- History of a solid organ allograft, or an inflammatory or autoimmune disease likely to be exacerbated by IL-2.
- Ongoing uncontrolled systemic infections.
- Positive HIV PCR test
- Positive for Hepatitis B or Hepatitis C
- Prior allogeneic stem cell transplant.
- Females of childbearing potential must be willing and able to use appropriate contraception for duration of trial and for 6 months following final AB-101 dose. Males must be sterile or commit to using appropriate contraception until 90 days following the final dose of AB-101.
- Individuals who are pregnant or lactating are ineligible.
- Patients who received a previous genetically modified cell therapy product (e.g., CD19 CAR-T), and progressed within 120 days from the time of the cell therapy infusion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 2: AB-101 given with rituximab or with BR to patients with B-cell NHL at the R2PD
Phase 2: AB-101 given with rituximab or with bendamustine and rituximab to patients with B-cell NHL at the R2PD
|
NK cell therapy
Anti-CD20 antibody therapy
Immune cytokine
Lymphodepleting chemotherapy
Lymphodepleting chemotherapy
Chemoimmunotherapy
|
Experimental: Phase 1: Dose confirmation of AB-101 as mono, ritux combo (including DLBCL specific) & BR combo
Phase 1: Dose confirmation of AB-101 as monotherapy, in combination with rituximab (including the DLBCL specific cohort) and in combination with bendamustine and rituximab
|
NK cell therapy
Anti-CD20 antibody therapy
Immune cytokine
Lymphodepleting chemotherapy
Lymphodepleting chemotherapy
Chemoimmunotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1, combination therapy: AB-101 clinical activity, determined by ORR
Time Frame: From baseline disease assessment through end of study participation.
|
Objective response rate (ORR) is defined as the proportion of patients with a documented complete response or partial response (CR + PR) in the absence of earlier disease progression.
|
From baseline disease assessment through end of study participation.
|
Phase 1, combination therapy: Identify the recommended Phase 2 dose (R2PD) for AB-101.
Time Frame: From ICF signature through 13 weeks after last study drug dose.
|
R2PD will be determined based on safety and tolerability of AB-101 in combination with rituximab or in combination with bendamustine and rituximab.
|
From ICF signature through 13 weeks after last study drug dose.
|
Phase 2: Determine the efficacy profile of AB-101 in combination with rituximab or in combination with bendamustine and rituximab when administered to patients with R/R NHL of B-cell origin.
Time Frame: From baseline disease assessment through end of study participation.
|
The efficacy profile will be determined by the ORR.
|
From baseline disease assessment through end of study participation.
|
Phase 1: Safety and tolerability of AB-101 as monotherapy, and in combination with rituximab (including the DLBCL specific cohort) and in combination with bendamustine and rituximab.
Time Frame: From the ICF signature through 13 weeks after last study drug dose.
|
Based on incidence, severity, and dose relationship of AEs and serious AEs (SAEs)
|
From the ICF signature through 13 weeks after last study drug dose.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Thorsten Graef, M.D., Ph.D., Artiva Biotherapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Lymphoma, Non-Hodgkin
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Immunological
- Cyclophosphamide
- Bendamustine Hydrochloride
- Rituximab
- Fludarabine
- Interleukin-2
Other Study ID Numbers
- AB-101-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Hodgkin Lymphoma
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
Acerta Pharma BVAstraZenecaActive, not recruitingNon Hodgkin LymphomaUnited States, Canada, Italy
Clinical Trials on AB-101
-
Asklepios Biopharmaceutical, Inc.RecruitingCongestive Heart FailureUnited States
-
Arbutus Biopharma CorporationRecruitingChronic Hepatitis bNew Zealand
-
Brainvectis, a subsidiary of Asklepios BioPharmaceutical...Active, not recruitingHuntington DiseaseFrance
-
AB Biotics, SACompletedModerate HypercholesterolemiaFrance
-
AnHeart Therapeutics Inc.Recruiting
-
Armata Pharmaceuticals, Inc.No longer available
-
Angiocrine BioscienceCalifornia Institute for Regenerative Medicine (CIRM)CompletedHodgkin Lymphoma | Non-hodgkin LymphomaUnited States
-
Alethia BiotherapeuticsCompletedSolid Tumor | Metastatic CancerCanada
-
Armata Pharmaceuticals, Inc.No longer available
-
Smart Medical Systems Ltd.UnknownInflammatory Bowel Diseases | Crohn Disease | Colitis, UlcerativeIsrael